Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Fig. 1

Overall survival (OS) and methylation levels of different patient cohorts. The Kaplan–Meier estimates of the OS for high-risk and low-risk patient cohorts grouping by the five-DNA methylation signature in the training dataset (N = 368) (a) and the validation dataset (N = 183) (b). The OS differences between the two groups were determined by the two-sided log-rank test. It can be concluded that higher risk scores are significantly associated with worse OS (P < 0.001). c Boxplots of methylation β values in samples of patients in high-risk and low-risk groups in the training dataset. “L” and “H” refer to the low-risk and high-risk group, respectively. Mann–Whitney U test was used to determine the differences between the two groups, and P values are shown below the graphs

Back to article page